103 related articles for article (PubMed ID: 17350673)
1. True difference or something else? Problems in cost of osteoarthritis studies.
Xie F; Thumboo J; Li SC
Semin Arthritis Rheum; 2007 Oct; 37(2):127-32. PubMed ID: 17350673
[TBL] [Abstract][Full Text] [Related]
2. Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies.
Xie F; Kovic B; Jin X; He X; Wang M; Silvestre C
Pharmacoeconomics; 2016 Nov; 34(11):1087-1100. PubMed ID: 27339668
[TBL] [Abstract][Full Text] [Related]
3. Socioeconomic impact of osteoarthritis in Hong Kong: utilization of health and social services, and direct and indirect costs.
Woo J; Lau E; Lau CS; Lee P; Zhang J; Kwok T; Chan C; Chiu P; Chan KM; Chan A; Lam D
Arthritis Rheum; 2003 Aug; 49(4):526-34. PubMed ID: 12910559
[TBL] [Abstract][Full Text] [Related]
4. The cost of schizophrenia: lessons from an international comparison.
Blomqvist AG; Léger PT; Hoch JS
J Ment Health Policy Econ; 2006 Dec; 9(4):177-83. PubMed ID: 17200594
[TBL] [Abstract][Full Text] [Related]
5. Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies.
Salmon JH; Rat AC; Sellam J; Michel M; Eschard JP; Guillemin F; Jolly D; Fautrel B
Osteoarthritis Cartilage; 2016 Sep; 24(9):1500-8. PubMed ID: 27034093
[TBL] [Abstract][Full Text] [Related]
6. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
7. Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States.
White AG; Birnbaum HG; Janagap C; Buteau S; Schein J
J Occup Environ Med; 2008 Sep; 50(9):998-1005. PubMed ID: 18784547
[TBL] [Abstract][Full Text] [Related]
8. Direct and indirect costs attributable to osteoarthritis in active subjects.
Rabenda V; Manette C; Lemmens R; Mariani AM; Struvay N; Reginster JY
J Rheumatol; 2006 Jun; 33(6):1152-8. PubMed ID: 16755664
[TBL] [Abstract][Full Text] [Related]
9. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.
Ray JA; Valentine WJ; Secnik K; Oglesby AK; Cordony A; Gordois A; Davey P; Palmer AJ
Curr Med Res Opin; 2005 Oct; 21(10):1617-29. PubMed ID: 16238902
[TBL] [Abstract][Full Text] [Related]
10. Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries.
Kingsbury SR; Gross HJ; Isherwood G; Conaghan PG
Rheumatology (Oxford); 2014 May; 53(5):937-47. PubMed ID: 24489012
[TBL] [Abstract][Full Text] [Related]
11. Projecting the direct cost burden of osteoarthritis in Canada using a microsimulation model.
Sharif B; Kopec J; Bansback N; Rahman MM; Flanagan WM; Wong H; Fines P; Anis A
Osteoarthritis Cartilage; 2015 Oct; 23(10):1654-63. PubMed ID: 26050868
[TBL] [Abstract][Full Text] [Related]
12. Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective.
Lee DW; Meyer JW; Clouse J
Value Health; 2001; 4(4):329-34. PubMed ID: 11705300
[TBL] [Abstract][Full Text] [Related]
13. Cost of epilepsy: a systematic review.
Strzelczyk A; Reese JP; Dodel R; Hamer HM
Pharmacoeconomics; 2008; 26(6):463-76. PubMed ID: 18489198
[TBL] [Abstract][Full Text] [Related]
14. The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition.
Gupta S; Hawker GA; Laporte A; Croxford R; Coyte PC
Rheumatology (Oxford); 2005 Dec; 44(12):1531-7. PubMed ID: 16091394
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
16. Productivity costs of work loss associated with osteoarthritis in Canada from 2010 to 2031.
Sharif B; Garner R; Hennessy D; Sanmartin C; Flanagan WM; Marshall DA
Osteoarthritis Cartilage; 2017 Feb; 25(2):249-258. PubMed ID: 27666512
[TBL] [Abstract][Full Text] [Related]
17. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern.
Zhu TY; Tam LS; Leung YY; Kwok LW; Wong KC; Yu T; Kun EW; Li EK
J Rheumatol; 2010 Jun; 37(6):1214-20. PubMed ID: 20360186
[TBL] [Abstract][Full Text] [Related]
18. Financial cost of osteoarthritis in France. The "COART" France study.
Le Pen C; Reygrobellet C; Gérentes I
Joint Bone Spine; 2005 Dec; 72(6):567-70. PubMed ID: 16226481
[TBL] [Abstract][Full Text] [Related]
19. The economic burden of prostate cancer.
Roehrborn CG; Black LK
BJU Int; 2011 Sep; 108(6):806-13. PubMed ID: 21884356
[TBL] [Abstract][Full Text] [Related]
20. Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies.
Jin X; Liang W; Zhang L; Cao S; Yang L; Xie F
Pharmacoeconomics; 2023 Nov; 41(11):1453-1467. PubMed ID: 37462839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
